Hem/Onc News

Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer On September 20, the US Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak, […]

Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: Review of Current Evidence and Future Directions

Abstract: Mantle cell lymphoma (MCL) is a heterogeneous and uncommon non-Hodgkin lymphoma that affects predominantly older patients and often is associated with an aggressive clinical […]

Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

H&O What type of drug is zanubrutinib? CT Zanubrutinib, also known as BGB-3111, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor. It inhibits BTK irreversibly […]

RT @DrHKantarjian: The field of #BPDCN is rapidly evolving | Our new article by Dr. Pemmaraju @doctorpemm highlights the new era of ta… https://t.co/JSFnWqi49W

11 months ago
RT @ChelseaPinnix: Great summary of the important work that’s been done to improve outcomes in a rare disease. The future is bright.… https://t.co/PmNK5VOwvT

11 months ago
“Blastic Plasmacytoid Dendritic Cell Neoplasm: Emerging Developments and Special Considerations for 2023” by Naveen… https://t.co/EAEfwKrGjU

12 months ago
“Novel Approaches to the Treatment of Multiple Myeloma” by Kathryn T. Maples, PharmD, Sara A. Scott, PharmD, and Sa… https://t.co/9fIXqRSXxe

12 months ago